Beckman Coulter seeks authorization for $4 antigen test
Beckman Coulter said it would file for an emergency use authorization for a SARS-CoV-2 antigen test that costs only $4.
Diagnostics giant Beckman Coulter sold to Danaher for $6.8B
Danaher Corp. (NYSE:DHR) agreed to pay about $6.8 billion in cash for Beckman Coulter Inc. (NYSE:BEC), ending weeks of jockeying for the Brea, Calif.-based diagnostics player.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Beckman Coulter buyer list dwindling
Some private equity firms have dropped out of the running for Brea, Calif.-based medical device and diagnostics maker Beckman Coulter Inc., while others have explored banding together for an acquisition.
Beckman Coulter ready for a VC buyout?
Several private equity firms are weighing a buyout of medical device and diagnostics maker Beckman Coulter Inc. (NYSE:BEC), according to news reports. Blackstone Group LP (NYSE:BX), Apollo Global Management LLC and Kohlberg Kravis Roberts & Co (NYSE:KKR) are among a handful of investment firms interested in the Brea, Calif.-based company after news surfaced that it was looking at strategic options, including a sale, according to Reuters.